

Pharmacy RHEUMATOLOGY REFERRAL FORM S-Z

877.RxHyVee (877.794.9833) 10004 S. 152nd Street, Suite C Omaha, NE 68138

Patient Information PLEASE FAX INSURANCE CARD (FRONT AND BACK)					Prescriber Information				
Last Name	First Name	irst Name DOB			Practice/Facility Name				
Address		Address							
City	State		ZIP		City State ZIP		ZIP	,	
SSN		Prescriber Name							
Sex ☐ Male ☐ Female	Weight (kg)		Height (ft,in)		Prescriber NPI				
Emergency Contact Phone		Phone	hone		Nurse/Key Contact Phone/Pager		Phone/Pager		
Insurance Plan	Plan ID #			Fax					
Diagnosis/Clinical Information PLEASE FAX CLINICAL AND LAB INFORMATION									
L40.54 Date of diagnosis/years with Prior Therapy: No Ye Concurrent Therapy: No	es (provide details): _ o Yes (provide de e):	thritis M	/145.9 Ankylosir		Other:	riatic Arthritis		-	
					S FOR USE			QTY	Refills
Simponi®	50 mg/0.5 ml SmartJect® Pen 50 mg/0.5 ml PFS			Inject 50mg SC once a month				1	
Simponi Aria® Current Weight:	50 mg/4 ml Vial			Infuse 2 mg/kg (mg) over 30 minutes at week 0				QS	
kg				Maintenance Dose: Infuse 2 mg/kg (mg) over 30 minutes at week 4 and then every 8 weeks thereafter				QS	0
Stelara Current Weight:	45 mg/0.5 ml PFS 90 mg/1 ml PFS			Initial Dose: Inject 45 mg SC on day 1 Inject 90 mg SC on day 1				1	0
kg (recommended dose for coexistent PsA & PsO in patients>100kg = 90mg)				Maintenance Dose: Inject 45 mg SC on day 29 and every 12 weeks thereafter Inject 90 mg SC on day 29 and every 12 weeks thereafter				1	
Taltz® (recommended dosing for PsA)	80 mg/ml Auto-injector 80 mg/ml Prefilled syringe			Initial Dose: Inject 160 mg (2-80 mg) SQ on day 1				2	0
				Maintenance Dose: Inject 80 mg SQ on day 28 and every 4 weeks thereafter				1	
Xatmep®	2.5 mg/ml oral solution			Takemg one time weekly				4 week supply	
(dosing for pJIA)									
Xeljanz®	5 mg tablet			Take one tablet by mouth once daily				30	
				Take one tablet by mouth twice daily				60	
Xeljanz XR®	11 mg XR tablet			Take one tablet by mouth once daily				30	
In order for a brand name product substitution:	to be dispensed, the pr	rescriber must l	nandwrite "Brand	Necessary" or "Br	and Medically Necessary	," or your state-spe	ecific required	language to	prohibit

PRODUCT SUBSTITUTION PERMITTED/Brand exchange permitted (date)

DISPENSE AS WRITTEN/Do Not Substitute

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.